The Jenner Institute, University of Oxford, Oxford, United Kingdom.
PLoS One. 2012;7(9):e44943. doi: 10.1371/journal.pone.0044943. Epub 2012 Sep 12.
Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals and humans. However, the induction of even higher level T cell responses may be crucial in achieving vaccine efficacy against difficult disease targets, especially in humans. Here we investigate the oligomerization domain of the α-chain of C4b-binding protein (C4 bp) as a candidate T cell "molecular adjuvant" when fused to malaria antigens expressed by human adenovirus serotype 5 (AdHu5) vectored vaccines in BALB/c mice. We demonstrate that i) C-terminal fusion of an oligomerization domain can enhance the quantity of antigen-specific CD4(+) and CD8(+) T cell responses induced in mice after only a single immunization of recombinant AdHu5, and that the T cells maintain similar functional cytokine profiles; ii) an adjuvant effect is observed for AdHu5 vectors expressing either the 42 kDa C-terminal domain of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(42)) or the 83 kDa ectodomain of P. falciparum strain 3D7 apical membrane antigen 1 (PfAMA1), but not a candidate 128kDa P. falciparum MSP1 biallelic fusion antigen; iii) following two homologous immunizations of AdHu5 vaccines, antigen-specific T cell responses are further enhanced, however, in both BALB/c mice and New Zealand White rabbits no enhancement of functional antibody responses is observed; and iv) that the T cell adjuvant activity of C4 bp is not dependent on a functional Fc-receptor γ-chain in the host, but is associated with the oligomerization of small (<80 kDa) antigens expressed by recombinant AdHu5. The oligomerization domain of C4 bp can thus adjuvant T cell responses induced by AdHu5 vectors against selected antigens and its clinical utility as well as mechanism of action warrant further investigation.
病毒载体疫苗已被证明能在动物和人类中诱导 T 细胞和抗体应答。然而,在针对困难疾病靶标的疫苗中,诱导更高水平的 T 细胞应答可能是至关重要的,尤其是在人类中。在这里,我们研究了 C4 结合蛋白(C4bp)α 链的寡聚化结构域作为候选 T 细胞“分子佐剂”,当其与由人腺病毒血清型 5(AdHu5)载体疫苗表达的疟疾抗原融合时,在 BALB/c 小鼠中。我们证明:i)在重组 AdHu5 单次免疫后,C 端融合寡聚化结构域可以增强抗原特异性 CD4+和 CD8+T 细胞应答的数量,且 T 细胞保持相似的功能性细胞因子谱;ii)观察到 AdHu5 载体表达的佐剂效应,包括 Plasmodium yoelii 裂殖子表面蛋白 1(PyMSP1(42)的 42kDa C 端结构域或 P. falciparum 株 3D7 顶膜抗原 1(PfAMA1)的 83kDa 外结构域,但候选的 128kDa P. falciparum MSP1 双等位基因融合抗原没有佐剂效应;iii)在 AdHu5 疫苗的两次同源免疫后,抗原特异性 T 细胞应答进一步增强,然而,在 BALB/c 小鼠和新西兰白兔中,未观察到功能性抗体应答的增强;iv)C4bp 的 T 细胞佐剂活性不依赖于宿主中功能性 Fc 受体 γ 链,而是与重组 AdHu5 表达的小(<80kDa)抗原的寡聚化相关。因此,C4bp 的寡聚化结构域可以佐剂 AdHu5 载体诱导的针对选定抗原的 T 细胞应答,其临床应用及其作用机制值得进一步研究。